Combining Anti-HIV Antibodies May Suppress Virus Without Antiretroviral Therapy
October 18th 2018Broadly neutralizing antibodies have one key advantage over antiretroviral therapy: they have a longer half-life and thus don’t require the daily, lifelong dosing regimen currently required of ART users.
Read More
CMS Officials Announce Plan to Require Price Transparency in Prescription Drug TV Ads
October 17th 2018Officials with the Centers for Medicare & Medicaid Services this week proposed requiring drug manufacturers to include prices in direct-to-consumer television advertisements for prescription drugs.
Read More
Positive Topline Results Shown for Dupilumab in Phase 3 Trials in Patients with CRSwNP
October 17th 2018A pair of pivotal Phase 3 placebo-controlled trials that evaluated dupilumab (Dupixent, Sanofi and Regeneron) for adults with inadequately-controlled chronic rhinosinusitis with nasal polyps met all primary and secondary endpoints.
Read More
Treatment for HER2-Negative Breast Cancer with Germline BRCA Mutation Granted FDA Approval
October 16th 2018Talazoparib, a poly ADP-ribose polymerase (PARP) inhibitor, is indicated for patients with known deleterious or suspected deleterious gBRCA-mutated breast cancer who are selected for the therapy based on an FDA-approved companion diagnostic.
Read More
CMS Officials Propose Requiring Drug Manufacturers to Disclose Drug Prices in TV Ads
October 16th 2018Officials with the Pharmaceutical Research and Manufacturing Association (PhRMA) said in a press release that they plan to request member companies’ direct-to-consumer (DTC) television advertisements to direct patients to information about medicine costs, including the list price of the medicine, out-of-pocket costs or other context about the potential cost of the medicine and available financial assistance.
Read More